mRNA Cancer Vaccines Work Without Key Immune Cells, US Study Finds

St. Louis, April 19, 2026 — Researchers at Washington University School of Medicine have found that mRNA cancer vaccines can trigger strong tumor-killing immune responses even in the absence of a key immune cell type, revealing an alternative biological pathway that could reshape vaccine design strategies for cancer treatment.

The findings, published in Nature, are based on experiments in mice and challenge long-held assumptions about how mRNA vaccines activate the immune system. Scientists discovered that a second subtype of immune cells can compensate when the traditionally required cells are missing, enabling effective anti-tumor responses.

mRNA vaccines activate immunity through dual cell pathways

mRNA vaccines work by delivering genetic instructions that prompt immune cells to produce specific proteins, which in turn train the immune system to recognize and attack diseased cells. In cancer applications, these proteins are designed to mimic tumor-specific markers, allowing immune cells to target and destroy cancerous tissue.

Previously, researchers believed that a subtype of dendritic cells known as cDC1 was essential for activating T cells, the immune system’s primary tumor-fighting agents. However, the new study shows that even when cDC1 cells are absent, the immune system can still mount a strong response.

The research identifies another dendritic cell subtype, cDC2, as capable of initiating T-cell activation. This discovery reveals that mRNA vaccines engage both cDC1 and cDC2 cells, rather than relying on a single pathway, broadening the understanding of immune system coordination.

Mouse models show tumor clearance without key cells

Using genetically modified mouse models, researchers tested immune responses in the absence of specific dendritic cell subtypes. Mice lacking cDC1 cells still produced strong T-cell responses after receiving mRNA vaccines.

These mice were also able to eliminate sarcoma tumors, which develop in connective tissues such as muscle, bone and blood vessels. The ability to clear tumors without cDC1 cells indicated that another mechanism was driving the immune response.

Further experiments confirmed that cDC2 cells were responsible for compensating in these cases. Mice lacking cDC2 cells, as well as those with both cell types intact, also showed effective immune responses and tumor rejection, demonstrating that both subtypes can independently contribute to cancer immunity.

Distinct immune signatures observed in T cells

The study found that T cells activated by cDC1 and cDC2 cells exhibited different molecular characteristics. These distinct “fingerprints” suggest that each pathway may influence the immune response in unique ways.

Understanding these differences could help researchers refine vaccine design by targeting specific immune pathways more precisely. This insight may also explain why some patients respond better to mRNA cancer vaccines than others.

The presence of multiple activation routes indicates that the immune system has built-in redundancy, which may enhance the effectiveness of mRNA-based therapies under varying biological conditions.

Unconventional mechanism identified in cDC2 activation

Researchers also uncovered a previously underappreciated mechanism by which cDC2 cells activate T cells. Instead of directly processing vaccine-derived proteins, cDC2 cells rely on other cells to generate and present protein fragments.

These fragments are then transferred to cDC2 cells through a process known as “cross dressing,” allowing them to present the antigen to T cells and initiate an immune response. This indirect pathway differs from traditional antigen presentation mechanisms associated with other vaccines.

The discovery of this process provides new insight into how mRNA vaccines function at a cellular level and highlights the complexity of immune system interactions during vaccination.

Findings may guide future cancer vaccine development

The study offers critical information for the development of next-generation mRNA cancer vaccines, which are currently being tested in clinical trials for conditions such as melanoma, small-cell lung cancer and bladder cancer.

By identifying multiple immune pathways involved in vaccine response, the research provides a framework for optimizing vaccine formulations, dosing strategies and patient selection. It also suggests that targeting both dendritic cell subtypes could improve therapeutic outcomes.

The findings come as mRNA technology, first widely deployed during the COVID-19 pandemic, continues to expand into oncology. Understanding how these vaccines interact with the immune system is considered essential for improving their effectiveness against complex diseases like cancer.

The study underscores the adaptability of the immune system and highlights new opportunities for leveraging mRNA platforms in cancer treatment by exploiting multiple cellular mechanisms rather than relying on a single pathway.